In the September 5, 2019 edition of The Legal Intelligencer, Edward T. Kang, Managing Member of KHF wrote “‘T.M. v. Janssen Pharmaceuticals’ – Lessons on Standards of Evidence.”
The value of the reinstatement of T.M. v. Janssen for lawyers is that it clarifies laws about evidence, how courts determine evidence’s reliability, and general lessons on procedural law.
Last month, the Pennsylvania Superior Court reinstated a case concerning the drug Risperdal, which had initially been dismissed mid-trial in 2016. Johnson & Johnson subsidiary Janssen Pharmaceutical’s drug, Risperdal, is currently the subject of thousands of suits alleging that the drug directly caused gynecomastia in many young men.